Physician profile
Ratika Sood
NPI 1174819312
$3,933.74
in general payments reported to CMS, 2019-2025
34 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.15 · 2022: $307 · 2023: $1,175 · 2024: $1,439 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,615.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $696.46 | 2022-2025 | Qulipta, Vraylar, Ubrelvy |
| Lilly USA, LLC | $482.67 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $451.48 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $287.47 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $246.67 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $197.16 | 2023-2025 | Veozah |
| Glaxosmithkline, LLC. | $173.78 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Axsome Therapeutics, INC. | $162.20 | 2023-2025 | Auvelity |
| Exact Sciences Corporation | $151.28 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lundbeck LLC | $135.91 | 2022-2025 | Vyepti, Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.12 | 2024-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.10 | 2023-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $82.84 | 2023-2025 | |
| Corcept Therapeutics | $73.73 | 2024-2025 | Korlym |
| Amgen INC. | $59.01 | 2024 | Krystexxa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $58.68 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $43.76 | 2023-2025 | Voquezna |
| Neurocrine Biosciences, INC. | $43.17 | 2023-2024 | Ingrezza |
| Horizon Therapeutics Plc | $37.89 | 2023 | Krystexxa |
| Merck Sharp & Dohme LLC | $29.03 | 2024 | |
| Daiichi Sankyo INC. | $27.91 | 2023 | Injectafer |
| Janssen Pharmaceuticals, INC | $27.56 | 2024 | Xarelto |
| Alkermes, INC. | $25.09 | 2025 | Aristada, Lybalvi |
| Bayer Healthcare Pharmaceuticals INC. | $22.63 | 2024 | |
| Sumitomo Pharma America, INC. | $22.58 | 2024 | Gemtesa |
| Seqirus USA INC | $22.44 | 2024 | Flucelvax, Fluad |
| Idorsia Pharmaceuticals US INC | $22.19 | 2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $19.10 | 2023 | Rexulti |
| Dynavax Technologies Corporation | $18.45 | 2024 | Heplisav-B |
| Life Molecular Imaging LTD | $17.83 | 2024 | Neuraceq |
| Dexcom, INC. | $17.23 | 2024 | Dexcom G6 Transmitter |
| Viatris Specialty LLC | $16.40 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $14.77 | 2023 | Evkeeza |
| Vertiflex, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ratika Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.